DISCOUNT ZERTIFIKAT - NOVO NORDISK ADR B | Real-time Bid/Ask 16:24:20 03/07/2024 BST | ||
| 99.73 EUR / 99.77 EUR | -1.50% |
|
| Current month | -0.42% | ||
| 1 month | +3.32% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 03/07/24 | 99.72 | -1.53% |
| 02/07/24 | 101.3 | -0.63% |
| 01/07/24 | 101.9 | +0.21% |
| 28/06/24 | 101.7 | +0.05% |
| 27/06/24 | 101.6 | -0.20% |
Delayed Quote Börse Stuttgart
Last update July 03, 2024 at 04:24 pm
More quotesStatic data
| Product type | Discount Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | ME79ET |
| ISIN | DE000ME79ET8 |
| Date issued | 22/01/2024 |
| Maturity | 20/06/2025 (352 Days) |
| Parity | 1 : 1 |
| Emission price | 88 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 102.2 € |
|---|---|
| Lowest since issue | 84.18 € |
| Spread | 0.02 € |
| Spread % | 0.02% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
993.5
DKK
Average target price
952.2
DKK
Spread / Average Target
-4.16%
- Stock Market
- Certificates
- Certificat
